Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis
Metrics: PDF 441 views | HTML 1211 views | ?
Yifei Chen1,*, Tao Wang2,*, Wei Wang1, Jiahao Hu1, Ruiting Li1, Shaojun He1 and Jiong Yang1
1Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P. R. China
2Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P. R. China
*These authors have contributed equally to this work
Jiong Yang, email: firstname.lastname@example.org
Keywords: NSCLC, SIRT1, overall survival, prognosis, meta-analysis
Received: February 25, 2017 Accepted: June 04, 2017 Published: July 12, 2017
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The prognosis of NSCLC is extremely poor and it is urgently to find a new marker. Numerous studies have confirmed that silent mating type information regulation 2 homolog-1 (sirtuin1; SIRT1) is abnormally expressed in NSCLC. This meta-analysis was performed to investigate the prognostic and clinicopathological significance of SIRT1 in NSCLC. A total of seven eligible studies, including 6 on clinicopathological features, 7 on prognosis were identified from the databases. Pooled hazard ratios (HRs) or odds ratios (OR) and 95% confidence intervals (95% CIs) were calculated using random- or fixed-effects models. Results revealed that high expression of SIRT1 was associated with poor overall survival in NSCLC patients (HR=1.99, 95% CI: 1.33-2.98, P=0.0009). Moreover, SIRT1 were related to histological grade (OR= 2.00, 95% CI= 1.05–3.78, P= 0.02) of NSCLC patients. In conclusion, our present meta-analysis indicated that SIRT1 may serve as a promising marker for prognosis of patients with NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.